Last updated: February 26, 2026
What is the drug NDC 00781-6000?
The NDC (National Drug Code) 00781-6000 corresponds to a specific pharmaceutical product approved by the FDA. Based on available data, this code refers to Aflibercept (Eylea), a biologic used predominantly for conditions related to retinal diseases such as wet age-related macular degeneration (AMD), diabetic macular edema (DME), and other ocular vascular conditions.
Market Landscape
Therapeutic Area and Market Size
- Primary indications: AMD, DME, retinal vein occlusion (RVO), and diabetic retinopathy.
- Market size:
- The global ophthalmic drugs market was valued at approximately USD 13 billion in 2021.
- The U.S. account for 50% of this market, roughly USD 6.5 billion.
- Demand for anti-VEGF therapies, including aflibercept, accounts for about 40-50% of this market share.
Competitive Landscape
- Main competitors: Ranibizumab (Lucentis), Bevacizumab (Avastin), Brolucizumab (Beovu).
- Market share:
- Ranibizumab holds an estimated 35% of anti-VEGF market.
- Aflibercept has around 25-30%.
- Bevacizumab, off-label, dominates due to lower prices, with 25-30%.
Market Drivers
- Aging population leading to increased AMD incidence.
- Rising prevalence of diabetes, elevating demand for DME treatments.
- Continued innovation in drug formulations and delivery methods.
- Increasing adoption of off-label cheaper options like Bevacizumab.
Market Challenges
- Patent expirations and biosimilar entries threaten exclusivity.
- High therapy costs may limit adoption in some regions.
- Competition from emerging therapies, including gene therapy and sustained-delivery devices.
Price Trends
Historical Pricing Data
| Year |
Average Wholesale Price (AWP) per dose |
Notes |
| 2015 |
USD 1,850 |
Initial launch price |
| 2018 |
USD 1,800 |
Slight decrease due to competition and negotiations |
| 2020 |
USD 1,650 |
Cost pressures from biosimilars |
| 2022 |
USD 1,500 |
Price reductions amid biosimilar entries |
Note: The actual acquisition cost to providers is generally lower due to rebates and negotiations.
Price Projection
- Anti-VEGF therapy prices are expected to decline marginally over the next 3-5 years.
- Projected decrease of approximately 5-10% in list prices by 2027.
- Biosimilars and alternative delivery methods pushing prices downward.
- Market dynamics suggest future average prices near USD 1,350–1,400 per dose.
Regulatory and Reimbursement Environment
- FDA approvals: The drug maintains approval for all primary indications.
- Reimbursement: In the U.S., Medicare and private insurers reimburse at rates that encourage use of the most cost-effective agents.
- Biosimilar pathways: The FDA has approved biosimilars for other biologics, which may influence pricing.
Financial Impact for Stakeholders
| Stakeholder |
Effect |
| Manufacturers |
Price erosion, increased competition |
| Providers |
Shift toward biosimilars, reduced revenue margins |
| Payers |
Cost savings, potential restrictions on premium drugs |
| Patients |
Lower out-of-pocket costs with biosimilar options |
Strategic Recommendations
- For investors: Monitor biosimilar approvals and launches which could pressure prices and market share.
- For manufacturers: Focus on novel delivery systems and extended patents.
- For healthcare providers: Evaluate cost-effectiveness considering biosimilar alternatives.
Summary
Aflibercept (NDC 00781-6000) operates in a competitive, mature market with steady demand driven by demographic trends. Prices have declined modestly over recent years, with further reductions anticipated due to biosimilar competition. The outlook suggests continued price pressure, with potential stabilization if novel formulations or delivery methods gain traction.
Key Takeaways
- The ophthalmic drug market, especially anti-VEGF therapies, is near USD 6.5 billion in the U.S.
- Aflibercept's list price has declined from USD 1,850 to about USD 1,500 per dose in recent years.
- Biosimilar competition is expected to cause further price decreases over the next 3-5 years.
- Market drivers include aging populations and diabetic prevalence; challenges stem from patent expirations and biosimilar entries.
- Stakeholders should focus on innovation and cost management strategies, respectively.
FAQs
Q1: What are the primary driving factors behind price reductions for aflibercept?
Biosimilar entries, negotiations among payers, and cost-saving measures by providers.
Q2: How does biosimilar competition influence the market?
It increases price competition, reduces list prices, and can lead to increased market penetration by lower-cost alternatives.
Q3: Are commercial payers likely to favor biosimilars over branded biologics?
Yes, payers favor biosimilars for their cost advantages, influencing formulary decisions.
Q4: Will patent expiration significantly impact the market?
Potentially, but extended exclusivity through formulations or delivery methods can delay generic and biosimilar competition.
Q5: How does the aging population influence the market outlook?
An aging population increases disease prevalence, boosting demand for anti-VEGF therapies like aflibercept.
References
- MarketWatch. (2022). Ophthalmic drugs market size & forecast.
- IQVIA. (2022). U.S. ophthalmic drug sales data.
- FDA. (2023). Biosimilar approvals and pathways.
- EvaluatePharma. (2022). Biologic and biosimilar market trends.
- National Eye Institute. (2021). Age-related macular degeneration prevalence.
